A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects

Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.

More from Cell & Gene Therapies

More from Advanced Technologies